SLC22A2 and familial primary hypomagnesemia: There are studies in animal models that suggest that hypomagnesemia enhances cisplatin accumulation in renal tissue by upregulating the organic cation transporter 2 (OCT2) transporter.28 Circulating levels of cisplatin have been shown up to 20 years after therapy, thus long-term renal effects are expected.15,29